Quarterly ResultMay 4, 2026, 04:32 PM
CRISPR Therapeutics Q1 Net Loss $122.9M; CASGEVY Revenue $43M
AI Summary
CRISPR Therapeutics reported a net loss of $122.9 million for Q1 2026, an improvement from $136.0 million in Q1 2025. The company generated $43 million in revenue from CASGEVY, with over 500 patients globally initiating treatment. Key pipeline advancements include the expansion of zugo-cel into new autoimmune indications, FDA clearance for CTX310's U.S. trial, and regulatory submission for pediatric CASGEVY. The company's cash position strengthened to $2.44 billion, driven by $585.4 million from convertible senior notes.
Key Highlights
- CASGEVY generated $43 million in Q1 2026 revenue.
- Net loss for Q1 2026 was $122.9 million, down from $136.0 million YoY.
- Cash, cash equivalents, and marketable securities totaled $2.44 billion.
- Received $585.4 million from convertible senior notes in March 2026.
- Over 500 people globally initiated CASGEVY treatment journey.
- R&D expenses decreased to $68.6 million from $72.5 million YoY.
- FDA cleared IND for CTX310, expanding trial into the U.S.
- FDA cleared IND for zugo-cel in autoimmune neurologic diseases.